Levonorgestrel Intrauterine System (Levosert®)

Assessment Status Rapid Review Complete
Drug Levonorgestrel Intrauterine System
Brand Levosert®
Indication For contraception and for the treatment of heavy menstrual bleeding.
Assessment Process
Rapid review commissioned 28/08/2019
Rapid review completed 23/10/2019
Rapid review outcome A full HTA is not recommended. The NCPE recommends that levonorgestrel-IUS (Levosert®) be considered for reimbursement.